Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: What lessons have we learnt and how can we do better?

European Respiratory Journal

Volumn 48, Issue 2, 2016, Pages 516-525

  Albert, Heidi ^a   Nathavitharana, Ruvandhi R ^b   Isaacs, Chris ^c   Pai, Madhukar ^d   Denkinger, Claudia M ^b,c   Boehme, Catharina C ^c  

^a FIND   (South Africa)

^b HARVARD MEDICAL SCHOOL   (United States)

^c FIND   (Switzerland)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEVICE APPROVAL; DEVICE FAILURE ANALYSIS; DEVICE MAINTENANCE; DRUG SENSITIVITY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LABORATORY INFORMATION SYSTEM; MEDICAL EDUCATION; MOLECULAR DIAGNOSTICS; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCALE UP; TUBERCULOSIS; TUBERCULOSIS CONTROL; TUBERCULOSIS RAPID TEST; ANTIBIOTIC RESISTANCE; COMMUNICABLE DISEASE CONTROL; DRUG EFFECTS; GLOBAL HEALTH; HEALTH CARE POLICY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POINT OF CARE TESTING; PRIVATE SECTOR; SPUTUM;

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTICS, ANTITUBERCULAR; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, BACTERIAL; GLOBAL HEALTH; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE TESTING; PRIVATE SECTOR; QUALITY ASSURANCE, HEALTH CARE; RIFAMPIN; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84980028010     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00543-2016     Document Type: Review

References (43)

1. Boehme C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
2. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
3. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-271.
4. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF. Policy statement. Geneva, World Health Organization, 2011.
5. Ramsay ARC, Steingart KR, Cunningham J, et al. Translating tuberculosis research into global policies: the example of an international collaboration on diagnostics. Int J Tuberc Lung Dis 2011; 15: 1283-1293.
6. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Geneva, World Health Organization, 2013.
7. World Health Organization. Updated: Xpert MTB/RIF implementation manual technical and operational "how-to": practical considerations. Geneva, World Health Organization, 2014.
8. Qin ZZ, Pai M, Van Gemert W, et al. How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? Eur Respir J 2014; 45: 549-554.
9. Medecins Sans Frontieres, Stop TB Partnership. Out of Step 2015 TB Policies in 24 Countries. Geneva, Medecins Sans Frontieres, 2015.
10. Scott L, Albert H, Gilpin C, et al. Multicenter feasibility study to assess external quality assessment panels for Xpert MTB/RIF assay in South Africa. J Clin Microbiol 2014; 52: 2493-2499.
11. Kik SV, Denkinger CM, Chedore P, et al. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J 2014; 43: 1793-1796.
12. Raizada N, Sachdeva KS, Sreenivas A, et al. Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India. PLoS One 2014; 9: e89301.
13. Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 2014; 14: 2.
14. Molapo S, Berrie L, Marokane P, et al. GeneXpert module failures: South Africa's Xpert MTB/RIF national programme experience and impact on costs. Int J Tuberc Lung Dis 2014; 18: Suppl. 1, S1.
15. Mookherji S, Mehl G, Kaonga N, et al. Unmet need: improving mHealth evaluation rigor to build the evidence base. J Health Commun 2015; 20: 1224-1229.
16. World Health Organization, European Respiratory Society. The role of e/mHealth in tuberculosis and tobacco control. 2015. Available from: www.who.int/tb/features-archive/emHealthinTBandtobaccocontrol.pdf
17. Denkinger CM, Dolinger D, Schito M, et al. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. J Infect Dis 2015; 211: Suppl 2, S39-S49.
18. Andre E, Isaacs C, Affolabi D, et al. Connectivity of diagnostic technologies: improving surveillance and accelerating TB elimination. Int J Tuberc Lung Dis 2016. In Press.
19. World Health Organization. Joint Inter-Ministerial Policy Dialogue on eHealth Standardization and Second WHO Forum on eHealth Standardization and Interoperability. Geneva, World Health Organization, 2014.
20. Starks AM, Avilés E, Cirillo DM, et al. Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform. Clin Infect Dis 2015; 61: Suppl 3, S141-S146.
21. Das J, Kwan A, Daniels B, et al. Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study. Lancet Infect Dis 2015; 15: 1305-1313.
22. Low M, Thom A. HIV positive: is South Africa winning? NSP Review 2013; 9: 1-45.
23. Pantoja A, Fitzpatrick C, Vassall A, et al. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J 2013; 42: 708-720.
24. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011; 8: e1001120.
25. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014; 383: 424-435.
26. Durovni B, Saraceni V, van den Hof S, et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med 2014; 11: e1001766.
27. Churchyard GJ, Stevens WS, Mametja LD, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015; 3: e450-e457.
28. Cox HS, Mbhele S, Mohess N, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med 2014; 11: e1001760.
29. Raizada N, Sachdeva KS, Sreenivas A, et al. Catching the missing million: experiences in enhancing TB and DR-TB detection by providing upfront Xpert MTB/RIF testing for people living with HIV in India. PLoS One 2015; 10: e0116721.
30. Raizada N, Sachdeva KS, Nair SA, et al. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB. PLoS One 2014; 9: e105346.
31. Sachdeva KS, Raizada N, Sreenivas A, et al. Use of Xpert MTB/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. PLoS One 2015; 10: e0126065.
32. Trajman A, Durovni B, Saraceni V, et al. Impact on patients' treatment outcomes of XpertMTB/RIF implementation for the diagnosis of tuberculosis: follow-up of a stepped-wedge randomized clinical trial. PLoS One 2015; 10: e0123252.
33. Masanja IM, Selemani M, Amuri B, et al. Increased use of malaria rapid diagnostic tests improves targeting of anti-malarial treatment in rural Tanzania: implications for nationwide rollout of malaria rapid diagnostic tests. Malar J 2012; 11: 221.
34. Pho MT, Deo S, Palamountain KM, et al. Optimizing tuberculosis case detection through a novel diagnostic device placement model: the case of Uganda. PLoS One 2015; 10: e0122574.
35. Langley I, Lin H-H, Egwaga S, et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Glob Health 2014; 2: e581-e591.
36. Baloch NA, Pai M. Tuberculosis control: business models for the private sector. Lancet Infect Dis 2012; 12: 579-580.
37. Salje H, Andrews JR, Deo S, et al. The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model. PLoS Med 2014; 11: e1001674.
38. Puri L, Oghor C, Denkinger CM, et al. Xpert MTB/RIF for tuberculosis: access and price in highly privatized health markets. Lancet Glob Health 2016; 4: e94-e95
39. Khan AJ, Khowaja S, Khan FS, et al. Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. Lancet Infect Dis 2012; 12: 608-616.
40. Dowdy DW, Lotia I, Azman AS, et al. Population-level impact of active tuberculosis case finding in an Asian megacity. PLoS One 2013; 8: e77517.
41. Denkinger CM, Kik SV, Cirillo DM, et al. Defining the needs for next generation assays for tuberculosis. J Infect Dis 2015; 211: Suppl 2, S29-S38.
42. Denkinger CM, Grenier J, Stratis AK, et al. Mobile health to improve tuberculosis care and control: a call worth making. Int J Tuberc Lung Dis 2013; 17: 719-727.
43. World Health Organization. The End TB Strategy. Geneva, World Health Organization, 2015.